Rheumatology Research Foundation
Balance Sheet
Fiscal Year Start:
Jul 1
Assets in 2024 (Year End)
$70,729,610
Investments
82%
Receivables (Non-Related)
14%
Cash & Equivalents
5%
Prepaid Expenses
<1%
Related-Party Receivables
0%
Inventories
0%
Property, Plant, & Equipment (net)
0%
Other Assets
0%
Liabilities in 2024 (Year End)
$1,605,570
Payables & Accruals
>99%
Grants Payable
0%
Deferred Revenue
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Other Liabilities
0%
Assets
2023
2024
Change
Cash & Equivalents
$8,600,923
$3,254,756
-62%
Receivables (Non-Related)
$11,513,000
$9,553,362
-17%
Related-Party Receivables
-
$0
-
Inventories
-
-
-
Prepaid Expenses
$87,105
$90,127
+3%
Investments
$50,295,515
$57,831,365
+15%
Property, Plant, & Equipment (net)
$0
$0
-
Other Assets
-
$0
-
Total Assets
$70,496,543
$70,729,610
+0%
Liabilities
2023
2024
Change
Payables & Accruals
$501,818
$1,605,570
+220%
Grants Payable
-
-
-
Deferred Revenue
-
-
-
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
$0
-
Other Liabilities
-
$0
-
Total Liabilities
$501,818
$1,605,570
+220%
Net assets
2023
2024
Change
Restricted Net Assets
$30,273,324
$21,374,748
-29%
Unrestricted Net Assets
$39,721,401
$47,749,292
+20%
Net assets
2023
2024
Change
Net assets
+$69,994,725
+$69,124,040
-1%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)